ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC).
OnKure has released preliminary safety, tolerability, and pharmacokinetic data from its first-in-human PIKture-01 trial of OKI-219, showing promising results in patients with advanced solid tumors, including breast cancer. The drug has been well tolerated across all tested dose levels, with no dose-limiting toxicities reported. The trial also highlights OKI-219's favorable pharmacokinetic profile and its potential in combination with standard therapies.
OnKure Inc. and Reneo Pharmaceuticals have completed a merger, resulting in OnKure Therapeutics, which now trades on the Nasdaq under the ticker symbol 'OKUR'.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.